AFFITOPE® PD03A
Neurodegenerative Diseases
Affiris AGPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
21 Active assets in the Neurodegenerative Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules Beijing Friendship Hospital | Phase 4 | BB |
Live Combined Bifidobacterium Beijing Friendship Hospital | Phase 4 | BB |
Lipitor Monash University | Phase 4 | BB |
Acp-103 Vanderbilt University Medical Center | Phase 4 | BB |
LEVODOPA Merck Sharp & Dohme LLC | Phase 2 | B |
View all 41 →
Same molecule, other indications
AFFITOPE® PD03A is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →